唑来膦酸联合椎体后凸成形治疗骨质疏松性压缩骨折：提高骨密度、预防椎体再骨折、远期疗效评价的Meta分析

文题释义：椎体后凸成形：采用椎体内置入气囊的方法通过扩张使椎体复位，在椎体内部形成空隙，减小骨水泥注入所需的推力，使骨水泥在椎体内不易流动，可有效解除或缓解疼痛、恢复病椎高度，但临床发现仍存在骨水泥渗漏等风险。 唑来膦酸：椎体后凸成形已被广泛应用于骨质疏松性压缩骨折的治疗，临床疗效显著，然而如何有效改善骨质疏松状况成为临床面临的重要问题。唑来膦酸是双膦酸盐类药物，可有效抑制骨吸收，降低再发骨折风险，改善骨折患者的功能评分。 背景：临床应用唑来膦酸治疗骨质疏松症缺乏系统的科学评价和循证学依据，因此目前对于唑来膦酸联合椎体后凸成形治疗骨质疏松性椎体压缩骨折的临床疗效尚无明确定论。 目的：系统评价唑来膦酸联合椎体后凸成形治疗骨质疏松性椎体压缩骨折的临床疗效。 方法：应用计算机检索公开发表在CNKI、万方、维普等中文数据库及CBM、PubMed、Cochrane等英文数据库中，有关唑来膦酸联合椎体后凸成形治疗骨质疏松性椎体压缩骨折的随机对照试验，试验组治疗方式为唑来膦酸联合椎体后凸成形，对照组治疗方式为椎体后凸成形，时间截止至2019年9月。由2位研究员独立进行文献筛选、数据提取，按Cochrane协作网标准对纳入随机对照试验逐个进行质量评价，采用RevMan 5.3软件对符合纳入标准的研究进行统计分析。 结果与结论：①最终纳入5篇文献，均为随机对照研究，试验组患者175例，对照组患者184例；②统计分析结果显示：试验组治疗后12个月的骨密度高于对照组[MD=0.12，95%CI(0.08，0.17)，P < 0.000 01]，治疗后6，12个月的目测类比评分低于对照组[MD=0.46，95%CI(0.18，0.75)，P=0.002；MD=0.85，95%CI(0.20，1.50)，P=0.01]，治疗后1年的Oswestry功能障碍指数评分低于对照组[MD=6.59，95%CI(4.77，8.41)，P < 0.000 01]，骨水泥渗漏率、椎体骨折再发率低于对照组[OR=0.22，95%CI(0.08，0.59)，P=0.003；OR=0.18，95%CI(0.07，0.50)，P=0.000 8]；两组椎体高度恢复、椎体后凸Cobb角比较差异无显著性意义[MD=0.65，95%CI(-0.27，1.56)，P=0.16；MD=-0.60，95%CI(-2.45，1.25)，P=0.53]；③结果表明与单独应用椎体后凸成形相比，唑来膦酸联合椎体后凸成形在提高骨密度值、减少椎体骨折再发率、改善患者远期临床症状、预防骨水泥骨水泥渗漏等并发症方面具有显著优势，但后期仍需大量高质量的多中心随机对照研究提供更充足的证据。 ORCID: 0000-0001-8871-3539(李凯明) 中国组织工程研究杂志出版内容重点：人工关节；骨植入物；脊柱；骨折；内固定；数字化骨科；组织工程     

Repurposing fallen leaves to bio-based reaction medium for hydration,hydroxylation, carbon-carbon and carbon-nitrogen bond formation reactions

A green reaction medium has been developed from the Water Extract of Teak leaf (Tectona grandis) ash (WET). The alkaline nature of the WET was successfully applied towards hydration of nitriles, conversion of arylboronic acids to phenols with 30% aqueous H₂O₂, Knoevenagel condensation for benzylidenemalononitrile derivatives formation and Chan-Lam reaction of arylboronic acids with imidazole derivatives. In current protocols dual role of WET as reaction medium as well as base has been explored. A wide range of substrates with varying electronic natures is compatible under these WET mediated reaction conditions with excellent yields.     

HPLC同时测定归芍疏肝散中芍药苷阿魏酸和甘草酸铵的含量

目的:建立同时测定归芍疏肝散中芍药苷、阿魏酸和甘草酸铵含量的高效液相色谱法。方法:采用Amethyst C18色谱柱(200 mm×4.6 mm,5μm),乙腈-0.1%磷酸为流动相,梯度洗脱,流速为1.0 mL·min-1,检测波长为237 nm,柱温为30℃。结果:在线性范围内3种成分线性良好(r≥0.9998),精密度RSD均<2%;重复性RSD均<3%;平均回收率98.81%~100.25%,RSD均<2%。结论:该方法快捷,操作简便,结果可靠,可用于归芍疏肝散的质量控制。     

黄褐斑的治疗新进展

黄褐斑是一种面部获得性色素增加性皮肤病,多发于东亚地区和肤色较深的个体(FitzpatrickⅢ~Ⅵ型),病因复杂、易复发,治疗困难。目前治疗以有效改善、控制病情为目标,以综合治疗为思路,尚没有单一特效的治疗方法。综合治疗多以防晒、修复皮肤屏障为基础,联合外用药物以及内用氨甲环酸、谷胱甘肽等,中重度可选择化学剥脱或激光、强脉冲光等。但化学剥脱以及美容激光对亚洲肤色人群有色素沉着、色素减退、肤色不均及复发等风险,临床上选择需十分谨慎。     

30%超分子水杨酸与低浓度甘醇酸在轻中度寻常性痤疮治疗中的疗效评价

目的:比较30%超分子水杨酸与低浓度甘醇酸治疗轻中度寻常性痤疮的疗效。方法:对2018年1月-2019年6月就诊于中国人民解放军总医院第一医学中心的86例轻、中度寻常性痤疮患者分别进行水杨酸或甘醇酸治疗,其中甘醇酸组48例,水杨酸组38例,共治疗3次,每次间隔时间2~3周,第1次治疗时、第2次治疗时、第3次治疗时及第3次治疗后4周随访(分别为V0、V1、V2、V3),记录患者痤疮分级、粉刺、炎性丘疹、脓疱、结节及GAGS评分。结果:V0时水杨酸治疗组粉刺17.00(13.00, 61.00)个、炎性丘疹32.00 (17.00, 67.00)个、 GAGS评分14.50 (14.00, 16.00)分;V0时甘醇酸治疗组粉刺24.50(11.00,44.00)个、炎性丘疹27.00(19.50,37.50)个、GAGS评分14.00(13.00,18.00)分。V3时水杨酸治疗组粉刺8.00(5.00,19.00)个、炎性丘疹20.00(10.00,22.00)个、GAGS评分11.00(9.00,13.00)分。V3时甘醇酸治疗组粉刺8.50(3.00, 21.00)个、炎性丘疹13.50 (10.00, 21.50)个、GAGS评分11.00 (9.50, 12.50)分。超分子水杨酸和低浓度甘醇酸两组间有效率及GAGS评分差异无统计学意义(P>0.05),两组内V3较V0皮疹减退率、有效率及GAGS评分差异均有统计学意义(P<0.05)。炎性丘疹方面甘醇酸组在治疗2次后较基线比差异有统计学意义,而水杨酸组在治疗3次后较基线比差异有统计学意义,两组治疗过程中均未出现明显不良反应。结论:30%超分子水杨酸与低浓度甘醇酸在轻中度寻常性痤疮治疗中均有效,在炎性丘疹治疗方面甘醇酸起效更快,但水杨酸的安全性略高。     

Assessing sialic acid content in food by hydrophilic chromatography-high performance liquid chromatography

We have established a novel hydrophilic chromatography (HILIC)-high performance liquid chromatography (HPLC) method to assess sialic acid content in food products. Single-factor and response surface methodologies (RSM) were used to systematically optimize the hydrolysis conditions of the food samples to extract the maximum amount of sialic acid. Chromatographic conditions were also adjusted. In foods containing sialic acid, we observed a strong linear relationship between sialic acid and peak area, ranging from 5 to 100 μg/mL (R² = 0.9998). The lowest detectable sialic acid concentration (RSN = 3) was 0.2 μg mL⁻¹, and the method detection limit was 0.02mg kg⁻¹. Sample recovery ranged from 95.85% to 99.78%, with an RSD of 1.46% (n = 6). Thus, the described method can be applied to the study of sialic acid content in foods.     

枳实薤白桂枝汤HPLC指纹图谱及10种指标成分含量测定研究

目的建立枳实薤白桂枝汤HPLC指纹图谱分析方法和复方中10种指标成分(辛弗林、槲皮素、桂皮酸、厚朴酚、柚皮苷、腺苷、香豆素、橙皮苷、和厚朴酚、新橙皮苷)含量测定方法,开展相关评价分析。方法采用HPLC法建立枳实薤白桂枝汤指纹图谱,开展相似度评价研究;测定复方中10个指标成分,分析复方中药材不同配伍对其量的变化影响;采用聚类分析等化学计量学方法,对获取相关数据进行分析,评价枳实薤白桂枝汤的质量控制相关指标的影响和价值。结果 10批样品的相似度在0.376～0.990,部分批次相似度大于0.9(5批),说明10批样品相似度差异较大。10批样品中S1～S3、S5、S6、S8、S10为一组,S4、S9为一组,S7单独为一组。共标定了30个特征峰,经主成分分析,主成分1～6是影响药材样品质量评价的主要因子;30个特征峰中对样品分组起关键作用的成分为21(新橙皮苷)、26、29(和厚朴酚)、3、23、17、30(厚朴酚)、5、24(香豆素)、28和7。含量测定结果显示,除槲皮素外,其余9种成分在测定的质量浓度范围内线性关系、精密度、稳定性和重复性良好;不同配伍会对药材中相关成分产生增加或抑制溶出的作用。结论所建立的HPLC方法可用于同时测定枳实薤白桂枝汤中10种化学成分的含量,该方法高效、准确、重复性好,可用于枳实薤白桂枝汤的质量控制和评价。     

New immunosuppressive agents in transplantation

Immunosuppressive agents have enabled the development of allogenic transplantation during the last 40 years, allowing considerable improvement in graft survival. However, several issues remain such as the nephrotoxicity of calcineurin inhibitors, the cornerstone of immunosuppressive regimens and/or the higher risk of opportunistic infections and cancers. Most immunosuppressive agents target T cell activation and may not be efficient enough to prevent allo-immunization in the long term. Finally, antibody mediated rejection due to donor specific antibodies strongly affects allograft survival.Many drugs have been tested in the last decades, but very few have come to clinical use. The most recent one is CTLA4-Ig (belatacept), a costimulation blockade molecule that targets the second signal of T cell activation and is associated with a better long term kidney function than calcineurin inhibitors, despite an increased risk of acute cellular rejection.The research of new maintenance long-term immunosuppressive agents focuses on costimulation blockade. Agents inhibiting CD40-CD40 ligand interaction may enable a good control of both T cells and B cells responses. Anti-CD28 antibodies may promote regulatory T cells. Agents targeting this costimulation pathways are currently evaluated in clinical trials.Immunosuppressive agents for ABMR treatment are scarce since anti-CD20 agent rituximab and proteasome inhibitor bortezomib have failed to demonstrate an interest in ABMR. New drugs focusing on antibodies removal (imlifidase), B cell and plasmablasts (anti-IL-6/IL-6R, anti-CD38…) and complement inhibition are in the pipeline, with the challenge of their evaluation in such a heterogeneous pathology.